Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab and Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
NCT07686796Phase 3Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2027
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in rectal cancer, sponsored by Guangdong Provincial People's Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07686796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686796.